No Homerun, But A Base Hit For Teva's Laquinimod
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva's Phase III ALLEGRO study shows the once-daily oral multiple sclerosis candidate still has promise, but efficacy data underwhelms.